Evidence map›Paper›PMID 37522176›Full record

Trial reportJournal of the American Heart Association2023

Cigarette Smoking as a Risk Factor for Hematoma Expansion in Primary Intracerebral Hemorrhage: Analysis From a Randomized Clinical Trial.

Alexander J Schupper, Mirhojjat Khorasanizadeh, Christina P Rossitto, Lydia D Foster, Christopher P Kellner, Jose I Suarez, Adnan I Qureshi, Shahram Majidi, ATACH‐2 trial investigators *

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Alexander J SchupperDepartment of Neurosurgery Mount Sinai Health System New York NY.ORCID 0000-0002-3322-8138
Mirhojjat KhorasanizadehDepartment of Neurosurgery Mount Sinai Health System New York NY.
Christina P RossittoDepartment of Neurosurgery Mount Sinai Health System New York NY.ORCID 0000-0001-8819-2198
Lydia D FosterDepartment of Public Health Sciences Medical University of South Carolina Charleston SC.ORCID 0000-0001-6856-5583
Christopher P KellnerDepartment of Neurosurgery Mount Sinai Health System New York NY.ORCID 0000-0003-4604-8205
Jose I SuarezDepartment of Neurology Johns Hopkins Hospital Baltimore MD.
Adnan I QureshiZeenat Qureshi Stroke Institute and Department of Neurology University of Missouri Columbia MO.ORCID 0000-0003-4962-540X
Shahram MajidiDepartment of Neurosurgery Mount Sinai Health System New York NY.ORCID 0000-0003-2971-6216
ATACH‐2 trial investigators *
Mount Sinai Health System · USJohns Hopkins Hospital · USRehabilitation Institute of Kansas City · USMedical University of South Carolina · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Cigarette smoking is a well-known risk factor for ischemic and hemorrhagic stroke. We evaluated the impact of smoking status on hematoma expansion and clinical outcome in patients with primary intracerebral hemorrhage. Methods and Results This is a post hoc exploratory analysis of the ATACH (Antihypertensive Treatment at Acute Cerebral Hemorrhage)-2 trial. Patients with intracerebral hemorrhage were randomized into intensive blood pressure lowering (systolic blood pressure, <139 mm Hg) versus standard blood pressure lowering (systolic blood pressure, 140-179 mm Hg) in this study. We compared the demographic characteristics; hematoma size, location, and expansion rate; and clinical outcome based on subjects' smoking status. Of a total of 914 patients in the trial with known smoking status, 439 (48%) patients were ever smokers (264 current smokers and 175 former smokers). Current and former smokers were younger and more likely to be men. Baseline Glasgow Coma Scale score and initial hematoma size did not vary based on smoking status. Ever smokers had higher rates of thalamic hemorrhage (42% versus 34%) and intraventricular hemorrhage (29% versus 23%); this rate was highest among former smokers versus current smokers (49% versus 35%, respectively). Ever smokers had a higher rate of hematoma expansion in 24 hours (adjusted relative risk [RR] [95% CI], 1.46 [1.08-1.96]) compared with nonsmokers on multivariate analysis. There was no significant difference in the rate of death and disability at 90 days between the 2 groups (adjusted RR [95% CI], 1.18 [0.998-1.40]). Conclusions Our analysis demonstrates cigarette smoking as an independent predictor for hematoma expansion. There was no significant difference in death and disability based on smoking status.

Indexed as

Cigarette SmokingAntihypertensive AgentsBlood PressureCerebral HemorrhageFemaleHematomaHumansMaleRisk FactorsTreatment OutcomeAntihypertensive Agentsintracerebral hemorrhageoutcomesrandomized clinical trialsmoking

Identifiers

PMID37522176
PMCPMC10492975
OpenAlexW4385406261

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.